– USA, TX – Aspira Women’s Health Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced the appointment of Dr. Celeste Fralick (Ph.D.) to its Board of Directors, effective February 23, 2022.
“We warmly welcome Celeste to our Board of Directors. She is an accomplished senior executive with exceptional leadership qualities. She will be a tremendous asset to our Board, and we look forward to her insights,” said Board chair, Jim LaFrance.
Valerie Palmieri, CEO added, “Celeste brings diverse data strategy expertise to the Board. As we expand our portfolio and incorporate additional data variables, her guidance and knowledge will be invaluable to the company.”
About Dr. Celeste Fralick
Dr. Fralick is an accomplished executive with over four decades of data strategy experience. She brings to the Board a broad background in technology and specifically healthcare in several markets with both customer and industry-facing experience. She has expertise in statistics, cybersecurity, system engineering, disability analyses, risk management, operations, quality systems, global regulatory affairs, clinical management, biotechnology, reliability, and data management. She has been recognized globally and cross-industry for leading-edge analytics, ideation, strategic leadership, and results-oriented competencies. Dr. Fralick was named to Forbes’ inaugural 2018 list of “Top 50 Women in Technology.”
Dr. Fralick said, “I am excited to join this dynamic company’s Board of Directors. I look forward to working with this team, which has been passionately committed to making a difference in women’s lives.”
Dr. Fralick recently retired as Chief Data Scientist at McAfee where she was responsible for developing enterprise and consumer product analytics and the data ecosystem. Before that, she was the Senior Principal Engineer, Chief Technology Officer of Analytics at Intel where she spent 22 years leading, developing, and implementing analytic strategy across various departments in the company, including a corporate-wide Analytic Center of Excellence. Before Intel, Dr. Fralick managed over 50 custom and module programs at Medtronic and was a divisional Product Assurance Manager at National Semiconductor/Fairchild Semiconductor. She began her career at Texas Instruments where she was a Quality/Reliability Engineering Manager.
Dr. Fralick earned a Ph.D. in Biomedical Engineering (focused on analytics, neural networks, neuroscience, and bioelectricity) from Arizona State University, an MSE in Biomedical Engineering from Arizona State University, and a BS in Microbiology/Chemistry from Texas Tech University.
About Aspira Women’s Health Inc.
Aspira Women’s Health Inc. is transforming women’s health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management, and improve gynecologic health outcomes for women. Aspira Women’s Health is particularly focused on closing the ethnic disparity gap in ovarian cancer risk assessment and developing solutions for pelvic diseases such as pelvic mass risk assessment and endometriosis. OVA1plus combines our FDA-cleared products, OVA1 and OVERA, to detect the risk of ovarian malignancy in women with adnexal masses. Aspira GenetiX testing offers both targeted and comprehensive genetic testing options with a gynecologic focus. With over 10 years of expertise in ovarian cancer risk assessment, Aspira Women’s Health is working to deliver a portfolio of pelvic mass products over a patient’s lifetime with our cutting-edge research. The next generation of products in development includes OVAWatch and EndoCheck. To improve patient accessibility, Aspira Women’s Health has recently launched our Aspira Synergy technology transfer platform to empower health systems, academics, regional labs, and physician group labs to conduct genetic and specialty tests in-house.
For more information: https://aspirawh.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.